Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

46.73 -0.75 (-1.58%)
Streaming Delayed Price Updated: 11:34 AM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment
From Scholar Rock
Via Business Wire
News headline image
Here's How Much You Would Have Made Owning Scholar Rock Holding Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
A Look Ahead: Scholar Rock Holding's Earnings Forecast ↗
 
Via Benzinga
News headline image
Why Scholar Rock Stock Wilted on Wednesday ↗
The market was hoping the company could better contain its losses. 
Via The Motley Fool
News headline image
Scholar Rock (SRRK) Q2 Loss Widens 63% ↗
Via The Motley Fool
News headline image
Scholar Rock Holding Corp (NASDAQ:SRRK) Reports Q2 2025 Wider Loss but Market Shows Optimism Ahead of Key FDA Decision ↗
Scholar Rock reports Q2 2025 loss of $0.98 per share but gains investor optimism ahead of FDA decision for apitegromab in SMA. Cash runway extends to 2027. 
Via Chartmill
News headline image
Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
News headline image
Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Stock Soars After Investigational Drug Helps Preserve Lean Mass: Retail Flags Lack Of Incremental Weight Loss ↗
Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said. 
Via Stocktwits
Topics Death
News headline image
Why Scholar Rock Shares Are Soaring Today ↗
Via The Motley Fool
Topics Stocks
News headline image
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study ↗
Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial. 
Via Benzinga
News headline image
Which stocks are gapping on Wednesday? ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
News headline image
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased ↗
Jefferies thinks big pharma companies are "still on the hunt" for deals. 
Via Stocktwits
News headline image
Greif Posts Upbeat Earnings, Joins Planet Labs PBC, IperionX, Owens & Minor And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the Jefferies Global Healthcare Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
News headline image
Earnings Scheduled For May 14, 2025 ↗
 
Via Benzinga
News headline image
Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Scholar Rock
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.